Alemtuzumab benefits kidney, pancreas transplant patients
Alemtuzumab appears to be associated with a lower incidence of acute rejection and infection compared with rabbit anti-thymocyte globulin (rATG) induction in kidney and pancreas transplant patients, regardless of age or ethnicity.